Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho IV rituximab Coverage Update | Ope…
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy 5.01.501

    Intravenous rituximab for non-oncologic indications

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy 5.01.501 alerts

    Get alerted when Policy 5.01.501 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical benefit coverage, criteria, and continuation rules for IV rituximab when used for non-oncologic conditions under Blue Cross of Idaho plans; affects providers requesting prior authorization for these indications.

    Policy Summary
    PayerBluecross Idaho
    PolicyIntravenous rituximab for non-oncologic indications
    Policy CodePolicy 5.01.501
    Change TypeNew policy added to prescription drug section
    Effective DateMar 1, 2026
    Last ReviewNov 20, 2025
    Next Review DateMar 1, 2026
    Key ActionObtain prior authorization and document meeting indication-specific criteria and trial/intolerance of preferred biosimilars when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    New policy added to the prescription drug section establishing IV rituximab for non-oncologic indications may be considered medically necessary if specified criteria are met.

    6HCPCS / Q-codes listed
    3Preferred biosimilars named
    4Boxed warnings
    lines of business

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Benefit exceptions noted
    >70References

    Coverage Criteria for IV Rituximab (Non‑Oncologic)

    Initial Treatment General Criteria

    Covered when ALL of the following are met for initial treatment

    product_preference: Request is for a preferred product (Riabni or Ruxience or Truxima) for Blue Cross of Idaho commercial plan members, unless documented contraindication/intolerance or inadequate therapeutic response to preferred products

    preferred products listed

    monotherapy_restriction: Rituximab is NOT used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator

    See Appendices for list

    dosing: Dosing is initiated in accordance with FDA-approved labeling and/or accepted drug compendia dosing

    Indication-specific Criteria (selected examples)

    Covered when ALL indication-specific criteria are met (examples below represent distinct indication groups with their own subcriteria)

    rheumatoid_arthritis: Individual is ≥18 years with moderate to severe rheumatoid arthritis AND inadequate response to methotrexate titrated to maximally tolerated dose OR if methotrexate is not tolerated/contraindicated inadequate response to other conventional therapy (sulfasalazine, leflunomide, or hydroxychloroquine); AND inadequate response/intolerance/contraindication to one or more TNF antagonist therapies
    gpa_mpa: Individual is ≥2 years with granulomatosis with polyangiitis or microscopic polyangiitis AND using rituximab concomitantly with glucocorticoids with or without avacopan for induction treatment OR using as follow-up after achieving disease control with induction
    autoimmune_blistering_diseases: Autoimmune blistering skin diseases: either as first-line treatment in adults with moderate to severe pemphigus vulgaris OR for treatment-refractory disease (examples include pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, cicatricial pemphigoid, epidermolysis bullosa acquisita, paraneoplastic pemphigus)

    examples listed

    tpp_ttp: Immune-mediated thrombotic thrombocytopenic purpura (TTP): ADAMTS13 activity <10% with presence of ADAMTS13 inhibitor or anti-ADAMTS13 IgG AND used with plasma exchange therapy and glucocorticoids for acute event/relapse OR used in remission to prevent relapse

    Continuation Therapy

    Continuation of therapy

    prior_approval_met: Coverage criteria for initiation of rituximab therapy for the requested indication has previously been met
    clinical_benefit: There is clinically significant and functionally relevant improvement or stabilization in clinical signs and symptoms of the disease
    monotherapy_restriction_continuation: Not to be used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator

    See Appendices

    Initial and Continuing Therapy

    IV rituximab for non-oncologic indications may be considered medically necessary when specified initial and continuing treatment criteria are met.

    Initial and continuing criteria: Initial and continuing treatment criteria are required for medical necessity as stated in the policy history summary; specifics are contained in earlier sections of the full policy.

    Full criteria not present in this fragment.

    Requests for IV rituximab may be considered NOT medically necessary when the individual has active or untreated latent tuberculosis, hepatitis B, other active serious infections, or a history of recurrent infections. This policy specifically lists these infectious conditions as denial triggers for continuation or initiation of therapy and requires that such risks be resolved before treatment is approved.

    This medical policy may not apply to all lines of business. Examples called out in the policy include the Federal Employee Program, Medicare Supplement, Medicare Advantage, Medicaid, and certain self‑insured groups. Providers should confirm applicability and any differing prior authorization requirements with the member’s specific benefit plan.

    No additional explicit exclusions for IV rituximab are provided in the cited fragments of the policy text. The document section cited here contains literature references and does not enumerate further exclusion language beyond other sections of the policy.

    The presence of procedure or diagnosis codes in the policy or appendices does not itself guarantee coverage. Coverage determinations and provider reimbursement are subject to the member’s benefit plan documentation and the written coverage position set forth in this medical policy, along with applicable legal and policy requirements.

    Examples of contraindications to methotrexate that may justify use of alternative therapies (and therefore affect prior‑therapy requirements) include: pregnancy or planning pregnancy, breastfeeding, significant liver disease or elevated transaminases, blood dyscrasias (thrombocytopenia, leukopenia, significant anemia), interstitial pneumonitis or pulmonary fibrosis, renal impairment, hypersensitivity, history of intolerance or adverse event, alcohol use disorder, myelodysplasia, and significant drug interactions. These contraindications are listed in the policy appendices and can be used to document exceptions to step‑therapy or preferred‑product requirements when submitting prior authorization requests.

    The policy states that requests for IV rituximab are considered not medically necessary when the specified medical necessity criteria are not met, including when a request is for a non‑preferred medication that does not meet the policy’s exception rules. Providers should ensure all initiation or continuation criteria are met and documented to avoid a denial on medical necessity grounds.

    In the document fragments provided there are no explicit standalone 'not medically necessary' statements beyond those tied to the specified criteria; much of the cited text in this section consists of bibliographic references rather than policy determinations.

    Where the policy’s required medical necessity criteria for initiation or continuation are not met, coverage is effectively not available under this policy. The policy history and continuation language make clear that IV rituximab for non‑oncologic indications is covered only when the initial and continuing treatment criteria are satisfied; failure to meet those criteria implies non‑coverage.

    Coding Guidance and Code Lists

    See Codes tablemixed
    No codes listed
    HCPCS / Q-codes for rituximab productsHCPCS
    J9312Injection, rituximab, (Rituxan) 10 mg.
    J9311Injection, rituximab 10 mg and hyaluronidase.
    Q5115Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg.
    Q5119Injection, rituximab-pvvr, biosimilar, (Ruxience), 10 mg.
    Q5123Injection, rituximab-arrx, biosimilar, (Riabni), 10 mg.
    ICD-10 diagnosis codes and ranges referencedICD-10
    B10.89Other human herpes virus infection.
    B20Human immunodeficiency virus [HIV] disease.
    D47.Z1Post-transplant lymphoproliferative disorder (PTLD).
    D47.Z2Castleman disease.
    D59.0Drug-induced autoimmune hemolytic anemia
    D59.1 - D59.19Other autoimmune hemolytic anemias.
    D66Hereditary factor VIII deficiency.
    D67Hereditary factor IX deficiency.
    D68.1Hereditary factor XI deficiency.
    D68.311Acquired hemophilia.
    1–10 of 45
    1/5
    ICD-10 diagnosis and transplant status codesICD-10
    T86.810 - T86.811Complications of lung transplant (and related transplant complication series as listed)
    T86.811 T86.818 - T86.819Other or Unspecified complications of lung transplant
    T86.819 T86.820 - T86.821Complications of skin graft (allograft) (autograft)
    T86.821 T86.828 - T86.829Other or unspecified complications of skin graft (allograft) (autograft)
    T86.830 - T86.831Complications of bone graft
    T86.831 T86.838 - T86.839Other or unspecified complication of bone graft
    T86.840 - T86.841Complications of corneal transplant
    T86.848 - T86.849Other or unspecified complication of corneal transplant
    T86.850 - T86.851Complication of intestine transplant
    T86.858 - T86.859Other or Unspecified complications of intestine transplant
    1–10 of 17
    1/2
    ICD-10 transplant status codes (continued)ICD-10
    Z94.81 Z94.89 - Z94.9Bone marrow transplant status; transplant organ and tissue status, unspecified
    Named biologic drugmixed
    rituximabRituxan, Riabni, Ruxience, Truxima (listed as biologic DMARDs)
    Coding noteN/A — see Codes table for HCPCS and ICD-10 guidance; inclusion of a code does not guarantee coverage
    Reference guidanceCoding provided for general reference only; follow member-specific benefit plan documentation
    Claim submissionInclude applicable diagnosis/transplant status codes from policy appendices when requesting prior authorization
    Contraindication examples
    Pregnancy/planning pregnancyPregnancy or planning pregnancy is listed as a contraindication to methotrexate and may justify use of alternative agents or exception to prior therapy requirements
    Significant liver disease/alcohol use disorder

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required — use preferred rituximab products first

    Prior authorization is required for intravenous (IV) rituximab for non-oncologic indications; for Blue Cross of Idaho commercial plan members, requests should be for a preferred product (Riabni, Ruxience, or Truxima) unless the member has a documented contraindication, intolerance, adverse response, or inadequate therapeutic response to all preferred products. Dosing must be initiated in accordance with FDA-approved labeling and/or accepted drug compendia.

    • Preferred products named: Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs).
    • Exceptions: documented contraindication, intolerance, adverse response, or inadequate therapeutic response to all preferred products.
    • Dosing must follow FDA labeling or accepted compendia.
    Note

    Verify line‑of‑business applicability

    This policy may not apply to all lines of business; benefit applicability and prior authorization requirements can vary by plan (examples include the Federal Employee Program, Medicare Supplement, Medicare Advantage, Medicaid, and certain self‑insured groups). Confirm member-specific benefit plan applicability before requesting authorization.

    Background and Scope

    Background: Rituximab is an intravenous anti‑CD20 monoclonal antibody used in a range of autoimmune and immune‑mediated conditions. This policy addresses IV rituximab for non‑oncologic indications and specifies initial and continuation criteria, preferred biosimilar products for commercial members, dosing per FDA labeling or accepted compendia, and restrictions against combining rituximab with other biologic or targeted synthetic DMARDs.

    Definitions and Key Terms

    Immune-mediated encephalitis
    DefinitionEncephalitis confirmed by detection of a specific autoantibody associated with encephalitis (examples include NMDAR, LGI1, Caspr2, AMPAR, GABA-A/B, IgLON5, DPPX, GlyR, mGluR1/2/5, Neurexin 3-alpha, D2R)
    Diagnostic requirementDetection of a specific autoimmune encephalitis antibody is required for the diagnosis referenced in the policy
    Treatment contextRituximab considered when individual has inadequate response to, is intolerant of, or has contraindication to first-line agents such as IVIG or plasma exchange
    Biosimilar
    DefinitionBiosimilar: a biological product approved based on data demonstrating it is highly similar to an FDA-approved reference product with no clinically meaningful differences in safety, purity, and potency
    Policy examples

    Initial Therapy Criteria

    Initial Therapy

    Initial therapy covered when preferred product and indication criteria met

    preferred_product_or_exception: Request is for a preferred product OR individual has documented contraindication/intolerance/adverse response to all preferred products or has used the preferred products with inadequate therapeutic response
    dosing_concordance: Dosing initiated per FDA labeling or accepted drug compendia

    Initial therapy

    Initial therapy eligibility references prior use of conventional and biologic DMARDs and contraindications to alternatives.

    Initial therapy: Initial treatment criteria required; policy includes lists of conventional, biologic, and targeted synthetic DMARDs to define prior therapies and potential contraindications (e.g., methotrexate contraindications). Specific step or failure requirements are in sections not included here.

    Continuation Therapy Criteria

    Continuation

    Continuation requests considered medically necessary when prior criteria met and clinical benefit demonstrated

    prior_criteria_met: Coverage criteria for initiation previously met
    clinical_improvement: Clinically significant and functionally relevant improvement or stabilization

    Continuation therapy

    Continuation treatment requires meeting continuing criteria designated by the policy.

    Continuation: Continuing treatment criteria are referenced in the policy history summary; details not present in this fragment. See full policy for specifics.

    See full policy for specifics.

    Step Therapy Requirements

    StepRequirement / NoteCoverage
    1Must trial preferred rituximab biosimilars (Riabni, Ruxience, Truxima) for Blue Cross of Idaho commercial plan members unless there is a documented contraindication, intolerance, adverse response, or inadequate therapeutic response to all preferred products
    StepRequirement / NoteCoverage
    1Placeholder — step definition not specified in this fragment (see full policy for specific step therapy operational details)
    StepGuiding lists referencedCoverage implication
    1Policy references lists of conventional, biologic, and targeted synthetic DMARDs (Appendix 1 and Appendix lists) and examples of methotrexate contraindications to inform prior therapy requirements (e.g., methotrexate contraindications include pregnancy, significant liver disease, blood dyscrasias, breastfeeding, renal impairment)

    Site of Care and Administration Setting

    Billing Rule

    IV rituximab covered under medical benefit

    Intravenous rituximab for non‑oncologic indications is covered under the medical benefit and should be administered in an infusion setting per the policy.

    Note

    Administer in setting with medical support

    Rituximab must be administered by IV infusion in settings with appropriate medical support (infusion center, hospital outpatient, or office) to manage severe infusion reactions.

    • Administered by a health care professional with appropriate medical support to manage severe and potentially fatal infusion reactions
    • Settings include infusion center, hospital outpatient, or office

    Biosimilar Preference and Related Notes

    Billing Rule

    Preferred rituximab products for commercial members

    Blue Cross of Idaho commercial plan members should be started on preferred rituximab biosimilars (Riabni, Ruxience, Truxima) per the policy’s biosimilar preference statement.

    • Preferred biosimilars: Riabni, Ruxience, Truxima
    Note
    Note
    Billing Rule

    Biosimilarity and HCPCS codes provided

    Biosimilarity for Riabni, Ruxience, and Truxima has been demonstrated as described in their full prescribing information; the policy lists corresponding HCPCS/Q‑codes for these products.

    • Biosimilarity statement per Full Prescribing Information

    Policy Revision History

    2025-11-20adoption

    Blue Cross of Idaho adopted a new policy for IV rituximab for non-oncologic indications and added it to the prescription drug section.

    2026-03-01effective_dateLatest

    Policy became effective and established that IV rituximab for non-oncologic indications may be considered medically necessary when specified criteria are met.

    Policy Summary
    PayerBluecross Idaho
    PolicyIntravenous rituximab for non-oncologic indications
    Policy CodePolicy 5.01.501
    Change TypeNew policy added to prescription drug section
    Effective DateMar 1, 2026
    Last ReviewNov 20, 2025
    Next Review DateMar 1, 2026
    Key ActionObtain prior authorization and document meeting indication-specific criteria and trial/intolerance of preferred biosimilars when applicable.
    SourceLink
    On This Page
    Coverage Criteria for IV Rituximab (Non‑Oncologic)Coding Guidance and Code ListsProvider Actions, Prior Authorization, and DocumentationBackground and ScopeDefinitions and Key TermsInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy RequirementsSite of Care and Administration SettingBiosimilar Preference and Related NotesPolicy Revision History
    pediatric_nephrotic: Pediatric nephrotic syndrome: individual ≤18 years with steroid-dependent, relapsing disease AND inadequate response to, intolerance of, or contraindication to corticosteroids or immunosuppressive agents (e.g., cyclosporine, cyclophosphamide, mycophenolate)
    membranous_nephropathy: Membranous nephropathy: moderate to high risk MN defined by proteinuria >3.5 g/day not decreased >50% after 6 months of conservative ACEi/ARB therapy OR estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2
    Clinical diagnosis of alcohol use disorder, alcoholic liver disease, or other chronic liver disease is an example that precludes methotrexate use
    BreastfeedingBreastfeeding is listed as a contraindication to methotrexate and informs prior therapy exceptions
    Blood dyscrasiasBlood dyscrasias (eg, thrombocytopenia, leukopenia, significant anemia) are contraindications influencing alternative therapy decisions
    History of intolerance or hypersensitivityPrior intolerance or hypersensitivity to methotrexate supports exception to prior therapy requirements
    • Benefit exceptions listed: Federal Employee Program, Medicare Supplement, Medicare Advantage, Medicaid, certain self‑insured groups.
    Prior Authorization

    Prior authorization — process details not in bibliographic sections

    The policy text in bibliographic sections does not state additional prior authorization process details beyond the medical‑necessity criteria; use the policy’s stated initial and continuing criteria and member plan rules when preparing an authorization request.

    • Policy history notes adoption and requirement to meet initial and continuing criteria for coverage (see policy history).
    Billing Rule

    Include HCPCS/Q‑codes on prior authorization requests

    Reference HCPCS/Q‑codes for rituximab and its biosimilars on authorization requests and claims: J9312, J9311, Q5115, Q5119, and Q5123 are listed in the policy coding section and should be used as applicable when submitting coverage requests.

    • HCPCS/Codes listed in policy: J9312; J9311; Q5115 (Truxima); Q5119 (Ruxience); Q5123 (Riabni).
    • The policy states that inclusion of a code does not guarantee coverage and benefit determinations are subject to member‑specific plan documentation.
    Prior Authorization

    Prior authorization required when seeking coverage — meet initial/continuation criteria

    IV rituximab was added to the prescription drug section and requires that requests meet the policy’s initial and continuing treatment criteria to be considered medically necessary; submit supporting documentation that the requested use meets those criteria.

    • New policy adoption effective 03/01/2026 adds IV rituximab for non‑oncologic indications to the prescription drug section.
    • Initial and continuing criteria must be met for coverage determination.
    Prior Authorization

    Preferred product requirement — start with named biosimilars for commercial members

    Commercial members should be started on preferred rituximab biosimilars (Riabni, Ruxience, Truxima); use of a non‑preferred rituximab product requires documentation of contraindication, intolerance, adverse response, or inadequate therapeutic response to all preferred products.

    • Preferred biosimilars named in the policy: Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs).
    • Documentation required to support use of non‑preferred agent: contraindication, intolerance, adverse response, or inadequate therapeutic response to preferred products.
    Note

    Clinical sequencing / combination therapy restriction

    There is limited data on concomitant use of rituximab with other biologic agents and with disease‑modifying antirheumatic drugs (other than methotrexate) for certain indications; the policy therefore restricts use of rituximab in combination with other biologic DMARDs, targeted synthetic DMARDs, or other immunomodulators (see Appendices).

    • Policy states limited data on concomitant use in RA, GPA, MPA, and pemphigus vulgaris.
    • Policy explicitly requires rituximab NOT be used in combination with other biologic or targeted synthetic DMARDs or other immunomodulators.
    Step Therapy

    No step‑therapy rules present in cited sections

    The policy’s provided excerpts do not include step therapy rules; specific step therapy steps or enforced sequencing are not present in the cited bibliographic fragments.

    • Policy references lists of DMARDs and methotrexate contraindications to inform prior‑therapy considerations, but explicit step rules are not shown in these chunks.
    Note
    Note

    DMARD lists inform prior‑therapy and step considerations

    Policy appendices list conventional, biologic, and targeted synthetic DMARDs that inform prior failure/intolerance requirements for rheumatologic indications; when prior‑therapy requirements are relevant, include documentation of trials or contraindications to the listed DMARDs.

    • Appendix 1 lists conventional DMARDs (e.g., methotrexate, leflunomide, mycophenolate, cyclosporine, azathioprine, cyclophosphamide, hydroxychloroquine, sulfasalazine).
    • Appendix lists biologic DMARDs (e.g., abatacept, adalimumab, infliximab, tocilizumab, rituximab) and targeted synthetic DMARDs (e.g., tofacitinib, baricitinib, upadacitinib).
    Documentation Required

    Required documentation — show indication and prior‑therapy history

    Submit documentation with authorization requests that the patient meets the indication‑specific criteria in the policy, and that prior trial/failure or documented contraindication or intolerance to preferred products has occurred when required.

    • Document which preferred products were tried and the clinical reason for switching (e.g., intolerance, contraindication, inadequate response).
    • Include evidence that the requested use meets the indication‑specific criteria described in the policy.
    Documentation Required

    Administration and safety documentation required

    Administer IV rituximab in a clinical setting by a healthcare professional with appropriate medical support to manage severe infusion reactions; document monitoring and any management of infusion reactions and boxed‑warning risks in the medical record.

    • Policy states rituximab should be administered by a health care professional with appropriate medical support to manage severe and potentially fatal infusion reactions.
    • Boxed warnings include fatal infusion reactions, severe mucocutaneous reactions, hepatitis B reactivation, and PML—document monitoring and safety measures accordingly.
    Note
    Billing Rule

    Coding guidance — codes are for reference; confirm member coverage

    Coding guidance is provided for reference only: inclusion of a code in the policy does not guarantee coverage; follow member‑specific benefit plan documentation and the written medical policy when submitting claims or authorization requests.

    • Policy caution: inclusion/exclusion of codes does not imply coverage or reimbursement eligibility.
    • Providers must follow member‑specific plan terms and other applicable policies.
    Documentation Required

    Include ICD‑10 diagnosis and transplant status codes on requests

    Include appropriate ICD‑10 diagnosis and, when applicable, transplant status codes from the policy appendices with prior authorization requests and claims; the policy provides extensive diagnosis and transplant status code lists in the coding section.

    • ICD‑10 diagnosis ranges and transplant status codes (e.g., T86.x series, Z94.0, Z94.81) are listed in the policy coding appendices.
    • Attach the relevant diagnosis and transplant status codes that support medical necessity when submitting requests.
    Denial Risk

    Denial triggers — active infections and non‑preferred agents

    Requests may be considered not medically necessary (denied) if the individual has active or untreated latent tuberculosis, active hepatitis B, other active serious infections, a history of recurrent infections, or if the request is for a non‑preferred medication without meeting the policy exceptions.

    • Policy explicitly lists active/untreated latent TB, hepatitis B, and other active serious infections as contraindications that may make requests not medically necessary.
    • Requests for non‑preferred medications are considered not medically necessary unless policy exceptions are met.
    Denial Risk

    Benefit line exclusions can cause denial

    Coverage may be excluded based on the member’s line of business; check whether the member’s plan (e.g., FEP, Medicare Supplement, Medicare Advantage, Medicaid, certain self‑insured groups) is subject to this policy or excluded prior to authorization submission.

    • If the member’s line of business is excluded, the request may be denied on that basis.
    Note
    Note

    Code inclusion does not guarantee coverage

    The presence of a code in the policy does not guarantee coverage for a given member; coverage determinations remain subject to the member‑specific benefit plan and the written coverage position in the medical policy.

    • Policy statement: inclusion of a code does not guarantee or imply any right to member coverage or provider reimbursement.
    Denial Risk

    Medical necessity requirement — failure to meet criteria risks denial

    Coverage will be denied if IV rituximab does not meet the policy’s specified medical necessity criteria; ensure all initial and continuing criteria in the policy are met and documented to avoid denial.

    • Policy history and continuation sections reiterate that initial and continuing treatment criteria must be met for medical necessity determinations.
    • Requests not meeting the criteria are considered not medically necessary.
    Riabni, Ruxience, and Truxima have demonstrated biosimilarity for conditions of use as described in their Full Prescribing Information
    ImplicationBiosimilar designation supports use as preferred products for commercial members per policy
    Neuromyelitis optica (NMO/NMOSD)
    Definition referenceNeuromyelitis optica (NMO/NMOSD) is referenced via diagnostic criteria and recommendations from sources such as the Neuromyelitis Optica Study Group (NEMOS) and related diagnostic guideline literature
    Evidence citedMeta-analyses and treatment outcome studies of rituximab in NMO/NMOSD are cited (eg, Gao et al. 2019; Damato et al. 2016; Kim et al. 2015)
    Clinical implicationPolicy recognizes guideline-supported diagnostic criteria (including aquaporin-4 antibody testing) when considering rituximab for NMO/NMOSD
    Chronic graft-versus-host disease (cGVHD)
    Definition referenceChronic graft-versus-host disease (cGVHD) is referenced through NIH consensus and systematic reviews addressing diagnosis and second-line treatment where rituximab has been evaluated
    Key citationsReferences include Dignan et al. (2012), Wolff et al. (2011), and systematic reviews/meta-analyses of rituximab in steroid-refractory cGVHD
    ContextPolicy cites cGVHD literature when considering rituximab as a second-line or steroid-refractory therapy option
    Guideline references
    Major society guidelines listedAmerican College of Rheumatology (ACR) guidelines (including 2024–2025 lupus and SLE guidance)
    Other guideline sourcesKDIGO clinical practice guidelines for glomerular diseases and lupus nephritis; ISHLT guidance for heart transplant care; ISTH and ASH guidance for TTP and ITP
    Additional referencesNICE MS management guidance and ATS recommendations for systemic sclerosis-associated ILD are also cited
    DMARDs (disease-modifying antirheumatic drugs)
    Conventional DMARDsExamples: methotrexate, azathioprine, cyclophosphamide, cyclosporine, hydroxychloroquine, leflunomide, mycophenolate, sulfasalazine
    Biologic DMARDsExamples: abatacept, adalimumab, anakinra, infliximab, tocilizumab, ustekinumab, rituximab (Rituxan/Riabni/Ruxience/Truxima), and others listed in Appendix 1/2
    Targeted synthetic DMARDsExamples: apremilast, baricitinib, deucravacitinib, tofacitinib, upadacitinib (listed in Appendix 3)
    Contraindications to methotrexate
    Pregnancy/planning pregnancyPregnancy or currently planning pregnancy is listed as a contraindication to methotrexate and may justify exceptions to prior therapy requirements
    Elevated liver enzymes / chronic liver diseaseClinical diagnosis of alcohol use disorder, alcoholic liver disease, or other chronic liver disease is an example that precludes methotrexate use
    Renal impairmentRenal impairment is listed as a contraindication to methotrexate and affects suitability of alternative DMARDs
    Pulmonary diseaseInterstitial pneumonitis or clinically significant pulmonary fibrosis is an example contraindication to methotrexate
    Hematologic abnormalitiesBlood dyscrasias such as thrombocytopenia, leukopenia, significant anemia, or myelodysplasia are contraindications to methotrexate

    Full initial criteria not in this fragment.

    Note

    No explicit site‑of‑care restrictions in citations

    The cited sections do not specify explicit site‑of‑care restrictions; use the policy guidance that rituximab is an IV infusion with setting considerations implied.

    Note
    Note

    Infusion‑setting considerations implied

    Policy pertains to IV rituximab and implies infusion‑setting considerations; follow the medical benefit policy for site‑of‑care decisions.

  1. HCPCS/Q‑codes listed for biosimilars (Q5115, Q5119, Q5123)
  2. Note
    Note
    Note
    Note